Infusion of Off-the-Shelf Ex Vivo Expanded Cryopreserved Cord Blood Progenitor Cells to Augment Single or Double Myeloablative Cord Blood Transplantation in Patients With Hematologic Malignancies.

Trial Profile

Infusion of Off-the-Shelf Ex Vivo Expanded Cryopreserved Cord Blood Progenitor Cells to Augment Single or Double Myeloablative Cord Blood Transplantation in Patients With Hematologic Malignancies.

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Jul 2018

At a glance

  • Drugs Dilanubicel (Primary) ; Ciclosporin; Cyclophosphamide; Fludarabine; Mycophenolate mofetil; Mycophenolate mofetil
  • Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Graft-versus-host disease; Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Adverse reactions; Biomarker; Therapeutic Use
  • Most Recent Events

    • 16 Jul 2018 According to a Nohla Therapeutics media release, the U.S. Food and Drug Administration (FDA) has granted dilanubicel (NLA101), Orphan Drug Designation for reduction of morbidity and mortality associated with hematopoietic stem cell transplant (HSCT). This designation was supported by the results of this study.
    • 15 Jun 2018 Results (5 years) presented in a Nohla Therapeutics media release.
    • 15 Jun 2018 According to a Nohla Therapeutics media release, long-term follow-up data from this study were presented at the 23rd Congress of European Hematology Association Annual Conference.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top